Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Mutualfunds logo

PRHSX T. Rowe Price Health Sciences

  • Fund
  • PRHSX
  • Price as of: Dec 14, 2018
  • $70.17
  • - $6.11
  • - 8.01%
  • Category
  • Health & Biotech Equities

PRHSX - Profile

Vitals

  • YTD Return -0.3%
  • 3 Yr Annualized Return 10.0%
  • 5 Yr Annualized Return 14.6%
  • Net Assets $13.1 B
  • Holdings in Top 10 37.1%

52 WEEK LOW AND HIGH

$70.17
$68.87
$84.58

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.77%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 37.50%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$2,500

IRA

$1,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return -0.3%
  • 3 Yr Annualized Total Return 10.0%
  • 5 Yr Annualized Total Return 14.6%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.01%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name T. Rowe Price Health Sciences Fund
  • Fund Family Name T. Rowe Price
  • Inception Date Dec 29, 1995
  • Shares Outstanding N/A
  • Share Class No Load
  • Currency USD
  • Domiciled Country United States
  • Manager Ziad Bakri

Fund Description

The T. Rowe Price Health Sciences Fund (PRHSX) is an actively managed, specialty mutual fund covering the health and biotech sectors. PRHSX is best suited for those investors who already have core equity positions and are looking for specialty exposure.

Managers of the fund use fundamental analysis to identify the best growth candidates from within the health care sector. As such, PRHSX provides exposure to a wide range of health care-related firms, including pharmaceuticals, biotech researchers, medical device companies, health insurers/benefits managers and hospital administrators/owners. Despite its narrow focus, expenses are on the low side. The fund is internally managed by T. Rowe Price.

PRHSX - Performance

Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -0.3% -91.4% 22.3% 66.07% 4
1 Yr 13.2% -14.8% 26.9% 36.04% 2
3 Yr 10.0% * -7.5% 20.8% 28.70% 2
5 Yr 14.6% * 5.7% 19.2% 13.08% 1
10 Yr 21.8% * 6.1% 21.8% 0.97% 1

* Annualized


Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
2017 19.1% -19.5% 43.9% 46.36% 3
2016 -14.2% -29.8% 14.5% 50.91% 3
2015 1.3% -20.4% 33.7% 22.73% 2
2014 17.6% -5.8% 48.1% 43.64% 3
2013 40.2% -3.1% 65.2% 48.62% 3

Total Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -0.3% -91.4% 22.3% 66.67% 4
1 Yr 13.2% -18.3% 26.9% 24.55% 2
3 Yr 10.0% * -14.2% 20.8% 23.15% 2
5 Yr 14.6% * 5.0% 19.2% 12.15% 1
10 Yr 21.8% * 6.1% 21.8% 0.97% 1

* Annualized


Total Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
2017 19.1% -19.5% 43.9% 46.79% 3
2016 -14.2% -25.1% 39.1% 53.21% 3
2015 14.4% -16.6% 100.0% 12.84% 1
2014 43.7% -5.8% 79.8% 19.27% 1
2013 100.6% 0.0% 398.7% 19.44% 1

NAV & Total Return History

PRHSX - Holdings

Filings data as of: Sep 30, 2018

Concentration Analysis

PRHSX Category Low Category High PRHSX % Rank Quintile
Net Assets 13.1 B 17.3 M 48.7 B 1.79% 1
Number of Holdings 121 29 370 7.14% 1
Net Assets in Top 10 4.83 B 9.85 M 20.9 B 1.79% 1
Weighting of Top 10 37.1% 23.6% 76.8% 24.11% 3

Top 10 Holdings

  1. UnitedHealth Group Inc 7.30%
  2. Cigna Corp 2.82%
  3. Becton, Dickinson and Co 4.86%
  4. Intuitive Surgical Inc 5.30%
  5. Vertex Pharmaceuticals Inc 3.83%
  6. Anthem Inc 2.97%
  7. Stryker Corp 2.44%
  8. Thermo Fisher Scientific Inc 2.71%
  9. Alexion Pharmaceuticals Inc 2.52%
  10. Merck & Co Inc 2.31%

Asset Allocation

Weighting Category Low Category High PRHSX % Rank Quintile
Stocks
99.53% 94.60% 99.89% 5.36% 1
Preferred Stocks
0.21% 0.00% 2.37% 8.04% 1
Convertible Bonds
0.14% 0.00% 0.27% 1.79% 1
Cash
0.13% 0.00% 4.96% 32.14% 5
Other
0.00% -2.67% 3.36% 11.61% 5
Bonds
0.00% 0.00% 4.69% 4.46% 5

Stock Sector Breakdown

Weighting Category Low Category High PRHSX % Rank Quintile
Healthcare
98.57% 12.47% 99.89% 2.68% 1
Technology
0.95% 0.00% 63.86% 20.54% 4
Utilities
0.00% 0.00% 0.30% 1.79% 5
Real Estate
0.00% 0.00% 1.16% 2.68% 5
Industrials
0.00% 0.00% 8.71% 11.61% 5
Financial Services
0.00% 0.00% 6.21% 7.14% 5
Energy
0.00% 0.00% 0.10% 1.79% 5
Communication Services
0.00% 0.00% 0.00% 0.89% 5
Consumer Defense
0.00% 0.00% 1.31% 10.71% 5
Consumer Cyclical
0.00% 0.00% 7.44% 8.93% 5
Basic Materials
0.00% 0.00% 0.51% 2.68% 5

Stock Geographic Breakdown

Weighting Category Low Category High PRHSX % Rank Quintile
US
94.91% 64.01% 99.69% 6.25% 1
Non US
4.62% 0.00% 35.88% 28.57% 5

PRHSX - Expenses

Operational Fees

PRHSX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 0.77% 0.10% 4.31% 64.29% 1
Management Fee 0.64% 0.09% 1.25% 12.50% 2
12b-1 Fee 0.00% 0.00% 1.00% 12.66% 1
Administrative Fee 0.15% 0.01% 0.40% 6.15% 4

Sales Fees

PRHSX Fees (% of AUM) Category Low Category High PRHSX Rank Quintile
Front Load N/A 2.50% 5.75% N/A N/A
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

PRHSX Fees (% of AUM) Category Low Category High PRHSX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PRHSX Fees (% of AUM) Category Low Category High PRHSX Rank Quintile
Turnover 37.50% 0.00% 699.00% 19.64% 3

PRHSX - Distributions

Dividend Yield Analysis

PRHSX Category Low Category High PRHSX % Rank Quintile
Dividend Yield 0.0% 0.00% 2.30% 47.83% 5

Dividend Distribution Analysis

PRHSX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

PRHSX Category Low Category High PRHSX % Rank Quintile
Net Income Ratio 0.01% -2.15% 1.44% 25.00% 2

Capital Gain Distribution Analysis

PRHSX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

PRHSX - Managers

Ziad Bakri

Manager

Start Date

Apr 01, 2016

Tenure

2.67

Tenure Rank

21.1%

Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment banking analyst positions in other investment firms


Tenure Analysis

Category Low

0.3

Category High

21.2

Category Average

9.4

Category Mode

3.9